AustraliaThe Australian Therapeutic Goods Administration (TGA) has issued a safety warning regarding GLP-1-based drugs, such as Ozempic, which may cause a rare but serious eye disorder known as non-arteritic anterior ischemic optic neuropathy (NAION). This condition can lead to permanent visual impairment or blindness and is characterized by sudden vision loss without pain. The TGA identified the potential link after reviewing a 2024 study published in JAMA Ophthalmology, which found a higher incidence of NAION among patients prescribed semaglutide compared to those on non-GLP-1 medications. As of now, 36 cases of NAION have been reported in Australia, with most linked to semaglutide. While the TGA advises caution and urges individuals to report vision changes, Optometry Australia cautions against unnecessary alarm and recommends stopping medication only if there is a noticeable change in vision. Dr. Flora Hui notes that approximately 70% of patients do not regain their vision once NAION develops, and certain risk factors like diabetes, sleep apnea, and hypertension increase susceptibility.
Bias read (Center): The article presents factual information about a medical safety warning issued by the TGA without overtly favoring any political ideology. It provides balanced reporting by citing both regulatory concerns and expert opinions from professional organizations like Optometry Australia. There is no clear
